MARKET

NVO

NVO

Novo Nordisk
NYSE

Real-time Quotes | Nasdaq Last Sale

72.44
+0.76
+1.06%
Opening 13:11 02/24 EST
OPEN
71.97
PREV CLOSE
71.68
HIGH
72.50
LOW
71.66
VOLUME
454.16K
TURNOVER
--
52 WEEK HIGH
75.86
52 WEEK LOW
49.24
MARKET CAP
131.30B
P/E (TTM)
24.51
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Top 15 Pharmaceutical Companies With Highest R&D Spending
In this article we are going to list the top 15 pharmaceutical companies with the highest R&D spending. Click to skip ahead and jump to the Top 5 Pharmaceutical Companies With Highest R&D Spending. Pharma companies have always been among the most important...
Insider Monkey · 3h ago
Global Diabetes Injection Pens Market 2020 Top Industry Trend and Segments Analysis upto 2025
Feb 23, 2021 (CDN Newswire via Comtex) -- MarketsandResearch.biz has published a report titled Global Diabetes Injection Pens Market 2020 by Manufacturers,...
CDN Newswire · 1d ago
Hormone Replacement Therapy Industry: Global Market Opportunities, Size, Share, Emerging Trends And Forecasts To 2027
Feb 23, 2021 (AmericaNewsHour) -- According to a recently published report by Research Nester on "Hormone Replacement Therapy Market: Global Demand Analysis...
AmericaNewsHour · 1d ago
Hemophilia A Therapeutics Market Latest Research On Industry Growth, Trends, Top Players, & Key Regions By 2027
Feb 23, 2021 (Heraldkeepers) -- Painful symptoms such as swelling joints, neck pain, fatigue, and prolonged headache are among the major signs of hemophilia....
Heraldkeepers · 1d ago
Human Insulin Drugs & Delivery Devices Market Research Report by Manufacturers, Region, Type and Application, Forecast to 2026
Feb 23, 2021 (Heraldkeepers) -- Raising population of the world has triggered many diseases that can't be controlled easily; lot of unhealthy living...
Heraldkeepers · 1d ago
Needles Market : Industry Development Scenario and Forecast
Japan, Japan, Tue, 23 Feb 2021 08:14:04 / Comserve Inc. / -- Needles Market With Top Countries Data, Industry Analysis by Regions, Size, Share, Revenue,...
Comserve · 1d ago
Diabetes Care Devices Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
Feb 23, 2021 (Market Insight Reports) -- The Global Diabetes Care Devices Market is estimated to value over USD 5.1 billion by 2027 end at a CAGR of over 16%...
Market Insight Reports · 1d ago
Biopharmaceutical Oral Drug Delivery Market- Rising Demand, Share and Healthy CAGR in the Upcoming Forecast 2027
Feb 23, 2021 (AmericaNewsHour) -- Recent report published by research nester titled "Biopharmaceutical Drug Delivery Market: Global Demand Analysis &...
AmericaNewsHour · 1d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NVO. Analyze the recent business situations of Novo Nordisk through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NVO stock price target is 81.05 with a high estimate of 81.70 and a low estimate of 80.40.
EPS
Institutional Holdings
Institutions: 943
Institutional Holdings: 146.13M
% Owned: 8.06%
Shares Outstanding: 1.81B
TypeInstitutionsShares
Increased
220
3.33M
New
121
-229.76K
Decreased
216
5.98M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.37%
Pharmaceuticals & Medical Research
+1.25%
Key Executives
Chairman/Independent Director
Helge Lund
President/Chief Executive Officer
Lars Fruergaard Joergensen
Vice Chairman/Director
Jeppe Christiansen
Chief Financial Officer/Executive Vice President/Primary Contact
Karsten Munk Knudsen
Chief Operating Officer/Executive Vice President
Maziar Doustdar
Executive Vice President/Chief Scientific Officer
Mads Krogsgaard Thomsen
Executive Vice President/Director of Human Resources
Monique Carter
Executive Vice President
Ludovic Helfgott
Executive Vice President
Doug Langa
Executive Vice President
Camilla Sylvest
Executive Vice President
Henrik Wulff
Director
Mette Boejer Jensen
Director
Kasim Kutay
Director
Anne Kverneland
Director
Thomas Rantzau
Director
Stig Stroebaek
Independent Director
Brian Daniels
Independent Director
Laurence Debroux
Independent Director
Andreas Fibig
Independent Director
Sylvie Gregoire
Independent Director
Liz Hewitt
Independent Director
Martin Mackay
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
--
Dividend USD 0.6830312
03/26/2021
08/06/2020
Dividend USD 0.3679776
08/14/2020
02/06/2020
Dividend USD 0.5613016
03/27/2020
08/09/2019
Dividend USD 0.31809
08/16/2019
03/26/2019
Dividend USD 0.557215
03/22/2019
08/21/2018
Dividend USD 0.327
08/17/2018
--
Dividend USD 0.578
03/23/2018
08/10/2017
Dividend USD 0.336
08/17/2017
03/28/2017
Dividend USD 0.479
03/23/2017
08/16/2016
Dividend USD 0.331
08/11/2016
03/24/2016
Dividend USD 0.699
03/18/2016
03/25/2015
Dividend USD 0.533
03/19/2015
03/27/2014
Dividend USD 0.606
03/21/2014
03/26/2013
Dividend USD 0.453
03/21/2013
  • All
  • Financials
  • Insiders
More
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Webull offers kinds of Novo Nordisk A/S (ADR) stock information, including NYSE:NVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVO stock methods without spending real money on the virtual paper trading platform.